McIlleron H - Search Results

1

Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.

Smythe W, Merle CS, Rustomjee R, Gninafon M, Lo MB, Bah-Sow O, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson US. Smythe W, et al. Among authors: mcilleron h. Antimicrob Agents Chemother. 2013 Sep;57(9):4164-71. doi: 10.1128/AAC.00479-13. Epub 2013 Jun 17. Antimicrob Agents Chemother. 2013. PMID: 23774436 Free PMC article. Clinical Trial.

2

Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G. Pillai G, et al. Among authors: mcilleron h. Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S309-16; discussion S317-21. Int J Tuberc Lung Dis. 1999. PMID: 10593710 Clinical Trial.

3

The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.

McIlleron H, Gabriels G, Smith PJ, Fourie PB, Ellard GA. McIlleron H, et al. Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S329-35; discussion S351-2. Int J Tuberc Lung Dis. 1999. PMID: 10593713 Clinical Trial.

4

Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.

McIlleron H, Wash P, Burger A, Folb P, Smith P. McIlleron H, et al. Int J Tuberc Lung Dis. 2002 Apr;6(4):356-61. Int J Tuberc Lung Dis. 2002. PMID: 11936746

5

Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.

Langdon G, Wilkins JJ, Smith PJ, McIlleron H. Langdon G, et al. Among authors: mcilleron h. Int J Tuberc Lung Dis. 2004 Jul;8(7):862-7. Int J Tuberc Lung Dis. 2004. PMID: 15260278 Clinical Trial.

6

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.

Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA. Sirgel FA, et al. Among authors: mcilleron h. Am J Respir Crit Care Med. 2005 Jul 1;172(1):128-35. doi: 10.1164/rccm.200411-1557OC. Epub 2005 Apr 1. Am J Respir Crit Care Med. 2005. PMID: 15805182 Clinical Trial.

7

Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.

Langdon G, Wilkins J, McFadyen L, McIlleron H, Smith P, Simonsson US. Langdon G, et al. Among authors: mcilleron h. Antimicrob Agents Chemother. 2005 Nov;49(11):4429-36. doi: 10.1128/AAC.49.11.4429-4436.2005. Antimicrob Agents Chemother. 2005. PMID: 16251279 Free PMC article.

8

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. McIlleron H, et al. Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7. doi: 10.1128/AAC.50.4.1170-1177.2006. Antimicrob Agents Chemother. 2006. PMID: 16569826 Free PMC article.

9

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Wilkins JJ, et al. Among authors: mcilleron h. Eur J Clin Pharmacol. 2006 Sep;62(9):727-35. doi: 10.1007/s00228-006-0141-z. Epub 2006 May 10. Eur J Clin Pharmacol. 2006. PMID: 16685561

10

Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs.

Gabriels GA, McIlleron H, Smith PJ, Folb PI, Fourie PB. Gabriels GA, et al. Among authors: mcilleron h. Int J Tuberc Lung Dis. 2007 Feb;11(2):181-8. Int J Tuberc Lung Dis. 2007. PMID: 17263289

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

212 results

Search Page

Filters